Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs
Companies launch neurology-focused incubator at Eisai s G2D2 facility in Cambridge, Mass.
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming to innovate in the complex field of neurological diseases. The incubator space is located at the Eisai Center for Genetics Guided Dementia Discovery (G2D2) facility and will become part of BioLabs national biotechnology network.